Roivant’s Lisraya Shows Promise in Uveitis as Cost Plus Drugs Expands Into Rare Disease Therapies

The need-to-know this morning

• Roivant and its subsidiary Priovant announced positive results across two Phase 3 studies of their drug Lisraya in non-infectious uveitis, an inflammatory eye disease that can lead to vision loss. Lisraya was recently approved to treat dermatomyositis, another inflammatory condition. Roivant said it will seek an expanded FDA approval for Lisraya in the first half of 2027.

Cuban’s Cost Plus Drugs is getting into rare disease

Mark Cuban’s Cost Plus Drugs, the online pharmacy that aims to lower drug costs by bypassing middlemen, has mostly been selling generic drugs. But the company is getting into a much more complicated field — experimental rare disease therapies.

The remainder of this article is available exclusively to STAT+ subscribers.

Source link